Description
NVP-AUY922 is an isoxazole-based inhibitor of heat shock protein 90 (HSP90) that displays anticancer chemotherapeutic and anti-angiogenic activities. NVP-AUY922 inhibits cell growth in pancreatic and colorectal cancer cells. In adult T-cell leukemia cells, NVP-AUY922 induces G1 phase cell cycle arrest and apoptosis, suppressing cell growth. Additionally, this compound induces tumor regression and decreases microvessel density in animal models of breast cancer, ovarian cancer, prostate cancer, and melanoma.
References
Kim SH, Kang JG, Kim CS, et al. Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells. J Clin Endocrinol Metab. 2015 Feb;100(2):E253-61. PMID: 25389633.
Taniguchi H, Hasegawa H, Sasaki D, et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Cancer Sci. 2014 Dec;105(12):1601-8. PMID: 25263741.
Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008 Apr 15;68(8):2850-60. PMID: 18413753.
